1
|
Dörr JR, Thorwarth A, Mizia-Malarz A, Radke J, Tietze A, Hernáiz-Driever P, Horn D, Gratopp A, Eggert A, Deubzer HE. Germline Mutations Including the Rare Pathogenic Variant c.3206delC in the ATM Gene Cause Ataxia Teleangiectasia-Associated Primary Central Nervous System Lymphoma. CHILDREN-BASEL 2021; 8:children8060469. [PMID: 34199532 PMCID: PMC8229184 DOI: 10.3390/children8060469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 05/20/2021] [Accepted: 05/27/2021] [Indexed: 11/16/2022]
Abstract
We here report the case of a 2-year-old patient with a primary central nervous system lymphoma of B-cell origin. Due to their past medical history of repeated respiratory tract infections and the marked chemotherapy-associated toxicity and infectious comorbidity, we suspected that the patient also suffered from an inherited immune deficiency disorder. Despite the lack of classical pathognomonic symptoms for ataxia teleangiectasia and missing evidence for a cancer predisposition syndrome in the family, genetic testing identified biallelic germline mutations, including the rare pathogenic variant c.3206delC (p.Pro1069Leufs*2), in the ataxia telangiectasia-mutated (ATM) gene. The case highlights the importance of searching for immune deficiency disorders associated with primary central nervous system lymphoma before treatment initiation and the urgent need to develop novel treatment strategies for cancer patients with underlying immunodeficiency syndromes.
Collapse
Affiliation(s)
- Jan R. Dörr
- Department of Pediatric Hematology and Oncology, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany; (J.R.D.); (A.T.); (P.H.-D.); (A.E.)
- Berliner Institut für Gesundheitsforschung (BIH), 10178 Berlin, Germany;
| | - Anne Thorwarth
- Department of Pediatric Hematology and Oncology, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany; (J.R.D.); (A.T.); (P.H.-D.); (A.E.)
| | - Agnieszka Mizia-Malarz
- Department of Pediatric Oncology, Hematology and Chemotherapy, Upper Silesia Children’s Care Health Center, Medical University of Silesia, 40-752 Katowice, Poland;
| | - Josefine Radke
- Berliner Institut für Gesundheitsforschung (BIH), 10178 Berlin, Germany;
- Department of Neuropathology, Charité–Universitätsmedizin Berlin, 10117 Berlin, Germany
- German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung; DKTK), Partner Site Berlin, 10115 Berlin, Germany
- German Cancer Research Center Heidelberg (Deutsches Krebsforschungszentrum; DKFZ), 69120 Heidelberg, Germany
| | - Anna Tietze
- Department of Neuroradiology, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany;
| | - Pablo Hernáiz-Driever
- Department of Pediatric Hematology and Oncology, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany; (J.R.D.); (A.T.); (P.H.-D.); (A.E.)
| | - Denise Horn
- Institute of Medical Genetics and Human Genetics, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany;
| | - Alexander Gratopp
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany
- Correspondence: (A.G.); (H.E.D.)
| | - Angelika Eggert
- Department of Pediatric Hematology and Oncology, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany; (J.R.D.); (A.T.); (P.H.-D.); (A.E.)
- Berliner Institut für Gesundheitsforschung (BIH), 10178 Berlin, Germany;
- German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung; DKTK), Partner Site Berlin, 10115 Berlin, Germany
- German Cancer Research Center Heidelberg (Deutsches Krebsforschungszentrum; DKFZ), 69120 Heidelberg, Germany
| | - Hedwig E. Deubzer
- Department of Pediatric Hematology and Oncology, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany; (J.R.D.); (A.T.); (P.H.-D.); (A.E.)
- Berliner Institut für Gesundheitsforschung (BIH), 10178 Berlin, Germany;
- German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung; DKTK), Partner Site Berlin, 10115 Berlin, Germany
- German Cancer Research Center Heidelberg (Deutsches Krebsforschungszentrum; DKFZ), 69120 Heidelberg, Germany
- Experimental and Clinical Research Center (ECRC) of the Charité–Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, 13125 Berlin, Germany
- Correspondence: (A.G.); (H.E.D.)
| |
Collapse
|
2
|
Long H, Li S, Zhang Y, Li R, Fong T, Yang C, Wang H, Xu N, Xu Y, Wang K, Yang K, Qi S, Wang J. Primary central nervous system T-cell lymphoma: An analysis from the surveillance, epidemiology, and end results program. J Clin Neurosci 2020; 79:74-79. [PMID: 33070923 DOI: 10.1016/j.jocn.2020.07.020] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2019] [Revised: 06/11/2020] [Accepted: 07/08/2020] [Indexed: 12/28/2022]
Abstract
BACKGROUND Primary central nervous system T-cell lymphoma (PCNSTCL) is a rare neoplasm with few data regarding its common features and survival characteristics. OBJECTIVE To explore the Surveillance, Epidemiology, and End Results 18 (SEER 18) database to determine the epidemiology of PCNSTCL. METHODS The SEER 18 registry database was queried to identify patients diagnosed with PCNSTCL from 1973 to 2014 and extract their information. Age-specific rates and Kaplan-Meier overall survival (OS) were calculated. A Cox proportional hazards model was applied to investigate relationships between various demographic/treatment variables and OS. RESULTS The age-specific incidence rates were higher in the older population (≥60 years). Among 59 PCNSTCL cases from the SEER 18, the mean age at presentation was 55.8 years (SD, ±17.95), with a male predominance (1.36:1.00). The median follow-up was 8 months, and the median OS was 8 months (SE, ±4.162). The 1-, 3-, and 5-year OS was 46.3% [95% CI, 33.4%-59.2%], 32.8% [20.3%-45.3%], and 32.8% [20.3%-45.3%], respectively. Seventeen of the 59 patients survived at last follow-up. Patients < 60 years had a greater 3-year OS compared with patients ≥ 60 years (52.6% [33.6%-71.6%] vs 13.9% [1.4%-26.4%]. Multivariate analysis has demonstrated that only age at diagnosis (≥60/<60 years) exhibited a significant relationship with OS (HR, 3.495 [1.688-7.235];p = 0.001). Sex (female/male) was observed to have a doubted trend towards significance (HR, 0.487 [0.231-1.030]; p = 0.060). CONCLUSIONS PCNSTCL is generally of poor prognosis but younger age at diagnosis (<60 years) predicts a better prognosis.
Collapse
Affiliation(s)
- Hao Long
- Department of Neurosurgery, Nanfang Hospital, Southern Medical University, China; The First Clinical Medicine College, Southern Medical University, China
| | - Siyi Li
- The First Clinical Medicine College, Southern Medical University, China; Neural Networks Surgery Team, Southern Medical University, China
| | - Yuzhen Zhang
- The First Clinical Medicine College, Southern Medical University, China; Neural Networks Surgery Team, Southern Medical University, China
| | - Ruqi Li
- The First Clinical Medicine College, Southern Medical University, China; Neural Networks Surgery Team, Southern Medical University, China
| | - Tszhei Fong
- Neural Networks Surgery Team, Southern Medical University, China; School of Basic Medical Science, Southern Medical University, China
| | - Chen Yang
- The First Clinical Medicine College, Southern Medical University, China; Neural Networks Surgery Team, Southern Medical University, China
| | - Hai Wang
- Department of Neurosurgery, Nanfang Hospital, Southern Medical University, China; The First Clinical Medicine College, Southern Medical University, China
| | - Nan Xu
- The First Clinical Medicine College, Southern Medical University, China
| | - Yuan Xu
- The First Clinical Medicine College, Southern Medical University, China; Neural Networks Surgery Team, Southern Medical University, China
| | - Kewan Wang
- Department of Neurosurgery, Nanfang Hospital, Southern Medical University, China; The First Clinical Medicine College, Southern Medical University, China
| | - Kaijun Yang
- Department of Neurosurgery, Nanfang Hospital, Southern Medical University, China; The First Clinical Medicine College, Southern Medical University, China
| | - Songtao Qi
- Department of Neurosurgery, Nanfang Hospital, Southern Medical University, China; The First Clinical Medicine College, Southern Medical University, China
| | - Jun Wang
- Department of Neurosurgery, Nanfang Hospital, Southern Medical University, China; The First Clinical Medicine College, Southern Medical University, China; Neural Networks Surgery Team, Southern Medical University, China.
| |
Collapse
|
3
|
Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis. Am J Surg Pathol 2016; 39:1719-1729. [PMID: 26379152 DOI: 10.1097/pas.0000000000000503] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Primary central nervous system (CNS) lymphomas are relatively rare with the most common subtype being diffuse large B-cell lymphoma. Primary CNS T-cell lymphomas (PCNSTL) account for <5% of CNS lymphomas. We report the clinical, morphologic, immunophenotypic, and molecular characteristics of 18 PCNSTLs. Fifteen cases were classified as peripheral T-cell lymphoma, not otherwise specified, 2 of which were of γδ T-cell derivation and 1 was TCR silent; there was 1 anaplastic large cell lymphoma, ALK-positive and 2 anaplastic large cell lymphoma, ALK-negative. Median age was 58.5 years (range, 21 to 81 y), with an M:F ratio of 11:7. Imaging results showed that 15 patients had supratentorial lesions. Regardless of subtype, necrosis and perivascular cuffing of tumor cells were frequently observed (11/18 cases). CD3 was positive in all cases but 1; 10/17 were CD8-positive, and 5/17 were CD4-positive. Most cases studied had a cytotoxic phenotype with expression of TIA1 (13/15) and granzyme-B (9/13). Polymerase chain reaction analysis of T-cell receptor γ rearrangement confirmed a T-cell clone in 14 cases with adequate DNA quality. Next-generation sequencing showed somatic mutations in 36% of cases studied; 2 had >1 mutation, and none showed overlapping mutations. These included mutations in DNMT3A, KRAS, JAK3, STAT3, STAT5B, GNB1, and TET2 genes, genes implicated previously in other T-cell neoplasms. The outcome was heterogenous; 2 patients are alive without disease, 4 are alive with disease, and 6 died of disease. In conclusion, PCNSTLs are histologically and genomically heterogenous with frequent phenotypic aberrancy and a cytotoxic phenotype in most cases.
Collapse
|
4
|
Cytotoxic Molecule-positive Epstein-Barr Virus-associated Peripheral T-cell Lymphoma in a 20-Month-old Child: A Case Report and Review of the Literature. J Pediatr Hematol Oncol 2015; 37:e475-80. [PMID: 26056791 DOI: 10.1097/mph.0000000000000368] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Peripheral T-cell lymphoma (PTCL) is rare in children. Expression of cytotoxic molecules (CM) in nodal PTCL has unique clinicopathologic features, including an Epstein-Barr virus (EBV) association. However, CM+, EBV-associated PTCL is extremely rare in the childhood, with only 1 study having been reported to date, including both pediatric and adult patients. We report a case of CM+ PTCL in a 20-month-old boy with left neck lymphadenopathy as well as multiple visceral lesions. A biopsied lymph node was diffusely infiltrated by atypical lymphoid cells with a CD4/CD8, granzyme B+, perforin+, and TIA-1+ phenotype, and EBV positivity by in situ hybridization. Rearrangements of the TCR γ-chain and β-chain genes were demonstrated by polymerase chain reaction. Ancillary genetic studies detected trisomy 2, trisomy 10, a structurally abnormal 6p, and additional copies of the IRF4 gene. Multiple bone marrow biopsies failed to show any evidence of tumor, histiocytic hyperplasia, or hemophagocytosis. This lesion was therefore diagnosed as "CM+, EBV-associated high-grade peripheral T-cell lymphoma." After 5 cycles of chemotherapy, the patient was in remission 8 months following initial diagnosis. To our knowledge, this represents the youngest child with this rare tumor in the published literature, and showing an unusually favorable initial response to therapy.
Collapse
|
5
|
Shalabi H, Angiolillo A, Vezina G, Rubenstein JL, Pittaluga S, Raffeld M, Marcus L. Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System. Pediatr Hematol Oncol 2015; 32:529-34. [PMID: 26384083 PMCID: PMC4942274 DOI: 10.3109/08880018.2015.1074325] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We describe a child with a 2-week history of progressive headaches, blurry vision, and intermittent vomiting. Magnetic resonance imaging (MRI) of the brain showed a deep left hemispheric lesion with extension into the corpus callosum. Histology and immunophenotyping of the lesion was consistent with peripheral T-cell lymphoma, not otherwise specified. Chemotherapy was initiated and a complete remission was achieved. This case illustrates that a chemotherapeutic regimen used in adults with central nervous system (CNS) lymphoma can achieve durable remissions in pediatric patients with peripheral T-cell lymphoma, not otherwise specified of the CNS.
Collapse
Affiliation(s)
- Haneen Shalabi
- Division of Pediatric Hematology and Oncology, Center for Cancer and Blood Disorders, Children’s National Medical Center, Washington, DC, USA
| | - Anne Angiolillo
- Division of Pediatric Hematology and Oncology, Center for Cancer and Blood Disorders, Children’s National Medical Center, Washington, DC, USA
| | - Gilbert Vezina
- Department of Radiology, Children’s National Medical Center, Washington, DC, USA
| | - James L. Rubenstein
- Division of Hematology and Oncology, University of California, San Francisco, California, USA
| | - Stefania Pittaluga
- Laboratory of Pathology, National Institutes of Health, Bethesda, Maryland, USA
| | - Mark Raffeld
- Laboratory of Pathology, National Institutes of Health, Bethesda, Maryland, USA
| | - Leigh Marcus
- Food and Drug Administration, Silver Spring, Maryland, USA
| |
Collapse
|
6
|
Primary peripheral T-cell lymphoma, not otherwise specified, of the central nervous system in a child. Brain Tumor Pathol 2015; 32:281-5. [PMID: 26334755 DOI: 10.1007/s10014-015-0229-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2015] [Accepted: 08/19/2015] [Indexed: 12/11/2022]
Abstract
Primary peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare disease that infrequently involves the central nervous system (CNS), and it is even rarer in pediatric patients. Here, we report of a 13-year-old male with primary CNS PTCL-NOS who exhibited a malignant clinical course with recurrence after radiochemotherapy followed by bone marrow transplantation; he died 43 months after diagnosis. Pathology revealed the proliferation of cytotoxic T-cells and clonal T-cell receptor gene rearrangements. Although the optimal therapy for PTCL remains controversial, intensive radiochemotherapy may be required for some patients.
Collapse
|
7
|
Mazur MD, Ravindra VM, Alashari M, Raetz E, Poppe MM, Bollo RJ. Primary T cell central nervous system lymphoblastic lymphoma in a child: case report and literature review. Childs Nerv Syst 2015; 31:977-84. [PMID: 25681952 DOI: 10.1007/s00381-015-2633-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Accepted: 02/03/2015] [Indexed: 11/27/2022]
Abstract
PURPOSE Primary central nervous system lymphoma (PCNSL) of T cell origin is rare in pediatric patients. We report a case of T cell PCNSL in a 12-year-old boy and review the literature to highlight the importance of brain biopsy to definitively establish the diagnosis when PCNSL is suspected. CASE REPORT A 12-year-old boy presented with worsening left-sided weakness, nausea, vomiting, headache, blurred vision, and diplopia. Magnetic resonance imaging revealed right parietal gyral thickening with faint meningeal contrast enhancement. No clear diagnosis was identified after serum testing, cerebrospinal fluid analysis, and cerebral angiography. To establish the diagnosis definitively, a right craniotomy and open, frameless stereotactic biopsy were performed, which yielded the diagnosis of lymphoblastic T cell lymphoma. CONCLUSIONS PCNSL of T cell origin in children remains poorly studied, with only 18 detailed cases reported over the last three decades, including this case. Establishing a definitive diagnosis of PCNSL is challenging, and a brain biopsy is often required to obtain enough tissue for pathological analysis. Increasing awareness and identification of children diagnosed with T cell PCNSL is needed to better understand the molecular biology of this disease and develop more standardized treatment regimens.
Collapse
Affiliation(s)
- Marcus D Mazur
- Division of Pediatric Neurosurgery, Department of Neurosurgery, Primary Children's Hospital, University of Utah, 100 North Mario Capecchi Drive, Suite 1475, Salt Lake City, UT, 84113-1100, USA
| | | | | | | | | | | |
Collapse
|